Skip to main content

Market access for medical technologies in Switzerland

A brief overview of key market access pathways and challenges for medical devices, in-vitro diagnostic tests in Switzerland

fghjh

Key topics

There are two key themes describing market access for medical technologies in Switzerland: 

  • Reimbursement: payment mechanism via DRG system, add-on reimbursement via ZE in hospital settings; payment via TARMED (soon to be replaced by TARDOC) catalog in out-patient settings
  • Funding: coverage decisions within the statutory health insurance by the Federal Office of Public Health

There is no health technology assessment challenge in Switzerland. HTA is integrated into funding decision-making.

Switzerland has one innovative payment scheme for medical technologies (Provisional reimbursement of medical procedures). 

sdf

Reimbursement

Reimbursement for hospital procedures is made solely via the SwissDRG system. All cases of hospitalization with at least one overnight stay are reimbursed via DRG. Day cases and outpatient care are completely separate from hospital care provisions and currently reimbursed via a fee-for-service model using the TARMED catalog. However, in 2026, the TARMED catalog is expected to be replaced by the TARDOC catalog for outpatient procedures and the outpatient flat-rates system for interventions performed in day case settings).

The DRG system has the following components:

Diagnosis-related groups

  • DRGs are determined by the combination of a procedure code (CHOP) and a diagnosis code (ICD-10-GM). CHOP nomenclature is maintained by the Federal Statistics Office (BFS/UFS) and released annually
  • The base rate is determined nationally, and the Cantons have to approve and adopt it. In case they do not adopt it, the Cantons may set their own base rate (rarely the case) 

Add-on reimbursement (Zusatzentgelt, ZE)

  • Add-on reimbursement is provided for expensive devices, procedures, and drugs
    Tariff is typically determined on the national level by the administrator of the DRG system, SwissDRG

The SwissDRG system is approved annually.

Procedures performed in out-patient and day case settings are reimbursed via a fee-for-service mechanism via the TARMED catalog (soon to be replaced).

sdxc

Funding

In the inpatient sector, medical devices/procedures are automatically reimbursed according to the so-called “principle of trust” unless they are questioned by a stakeholder of the system (typically insurance companies). In this case, the Federal Office for Public Health (FOPH) evaluates the questioned device/procedure and develops a coverage decision. 

dcvd

Specifics for IVD tests

In-vitro diagnostic tests are reimbursed using a fee-for-service mechanism via the List of Analyses (Annex 3 of the Healthcare Benefit Ordinance, KLV/OPre) in out-patient settings.

MTRC has experience with more than 173 projects in Switzerland

News and insights

2026 campaign for CHOP and SwissDRG system changes open in Switzerland

The application window for changes in the Swiss Classification of Surgical Procedures (CHOP) is open from June 1 to September 14, 2026. The application window for changes in the SwissDRG system is open from June 1 to July 13, 2026. The eligible applicants in both processes are limited to system stakeholders.

First revision of the new Swiss outpatient reimbursement system submitted for approval

On June 2, 2026, OAAT AG and the tariff partners submitted the 2027 revision of the new Swiss comprehensive outpatient reimbursement system to the Federal Council for approval. The revision further develops the new system introduced in January 2026, incorporating feedback from the annual application process and focusing on updates to outpatient flat rates and TARDOC across nuclear medicine, surgery, pathology, pediatrics, and emergency care. If approved, the revised version will take effect on January 1, 2027.

New add-on reimbursement categories for burn treatment with skin substitutes in Switzerland

At the end of March, the entity managing the DRG system in Switzerland, SwissDRG, established several unscheduled add-on reimbursement categories (ZE) for the treatment of burns with skin substitutes (autogeneic, allogeneic, alloplastic, xenogeneic). These ZE categories are valid from January 1, 2026, until December 31, 2026, for use in specific Swiss burn centers.

Get in touch

Contact us to discuss your needs and learn about our services